These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 34545722)

  • 1. [Herd immunity to SARS-CoV-2 in the Novosibirsk Region population amid the COVID-19 pandemic].
    Popova AY; Smirnov VS; Ezhlova EB; Mel'nikova AA; Samoilova LV; Lyalina LV; Semenova EV; Gurskiy MA; Aksenova EA; Arbuzova TV; Totolian AA
    Vopr Virusol; 2021 Sep; 66(4):299-309. PubMed ID: 34545722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
    Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal Randomized Cohort Study of SARS-CoV-2 Antibody Seroprevalence in the St. Petersburg Population.
    Smirnov VS; Lyalina LV; Milichkina AM; Khamitova IV; Zueva EV; Ivanov VA; Zaguzov VS; Totolian AA
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 herd immunity of the Kyrgyz population in 2021.
    Popova AY; Kasymov OT; Smolenski VY; Smirnov VS; Egorova SA; Nurmatov ZS; Milichkina AM; Suranbaeva GS; Kuchuk TE; Khamitova IV; Zueva EV; Ivanov VA; Nuridinova ZN; Derkenbaeva AA; Drobyshevskaya VG; Sattarova GZ; Kaliev MT; Gubanova AV; Zhimbaeva OB; Razumovskaya AP; Verbov VN; Likhachev IV; Krasnov AV; Totolian AA
    Med Microbiol Immunol; 2022 Aug; 211(4):195-210. PubMed ID: 35780233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Seroprevalence of anti-SARS-CoV-2 IgG/IgM antibodies in Borgosesia (Piedmont Region, Northern Italy) population: a surveillance strategy in post-lockdown period?].
    Alessi D; Borré S; Barale A; Isabella A; Milano F; Rossi MA; Silano V; Piu N; Cena T; Faggiano F;
    Epidemiol Prev; 2020; 44(5-6 Suppl 2):200-206. PubMed ID: 33412811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2 Infection in Portugal in May-July 2020: Results of the First National Serological Survey (ISNCOVID-19).
    Kislaya I; Gonçalves P; Barreto M; Sousa R; Garcia AC; Matos R; Guiomar R; Rodrigues AP;
    Acta Med Port; 2021 Feb; 34(2):87-94. PubMed ID: 33641702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival.
    Díaz-Salazar C; Sánchez-García A; Rodríguez-Gutiérrez R; Camacho-Ortiz A; Saldívar-Rodríguez D; González-González JG
    BMC Infect Dis; 2021 Aug; 21(1):835. PubMed ID: 34412620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.
    Gozlan Y; Reingold S; Koren R; Halpern O; Regev-Yochay G; Cohen C; Biber A; Picard O; Mendelson E; Lustig Y; Mor O
    Epidemiol Infect; 2021 Jun; 149():e153. PubMed ID: 34372950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão.
    Silva AAMD; Lima-Neto LG; Azevedo CMPES; Costa LMMD; Bragança MLBM; Barros Filho AKD; Wittlin BB; Souza BF; Oliveira BLCA; Carvalho CA; Thomaz EBAF; Simões-Neto EA; Leite Júnior JF; Cosme LMSS; Campos MAG; Queiroz RCS; Costa SS; Carvalho VA; Simões VMF; Alves MTSSBE; Santos AMD
    Rev Saude Publica; 2020; 54():131. PubMed ID: 33331525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
    Barchuk A; Skougarevskiy D; Kouprianov A; Shirokov D; Dudkina O; Tursun-Zade R; Sergeeva M; Tychkova V; Komissarov A; Zheltukhina A; Lioznov D; Isaev A; Pomerantseva E; Zhikrivetskaya S; Sofronova Y; Blagodatskikh K; Titaev K; Barabanova L; Danilenko D
    PLoS One; 2022; 17(6):e0266945. PubMed ID: 35704649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic.
    Dickson E; Palmateer NE; Murray J; Robertson C; Waugh C; Wallace LA; Mathie L; Heatlie K; Mavin S; Gousias P; Von Wissman B; Goldberg DJ; McAuley A
    Public Health; 2021 Jan; 190():132-134. PubMed ID: 33453689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 seroprevalence among blood donors after the first COVID-19 wave in Canada.
    Saeed S; Drews SJ; Pambrun C; Yi QL; Osmond L; O'Brien SF
    Transfusion; 2021 Mar; 61(3):862-872. PubMed ID: 33527398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe acute respiratory syndrome-coronavirus-2 seroprevalence study in Pimpri-Chinchwad, Maharashtra, India coinciding with falling trend - Do the results suggest imminent herd immunity?
    Banerjee A; Gaikwad B; Desale A; Jadhav SL; Rathod H; Srivastava K
    Indian J Public Health; 2021; 65(3):256-260. PubMed ID: 34558487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study.
    Ristić M; Milosavljević B; Vapa S; Marković M; Petrović V
    PLoS One; 2021; 16(7):e0254516. PubMed ID: 34242377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.
    Herlinda O; Bella A; Kusnadi G; Swasthika Nurshadrina D; Thoriq Akbar M; Nida S; Salama N; Ariawan I; Saminarsih D
    PLoS One; 2021; 16(12):e0261931. PubMed ID: 34941968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of SARS-CoV-2, Symptom Profiles and Sero-Neutralization in a Suburban Area, France.
    Gégout Petit A; Jeulin H; Legrand K; Jay N; Bochnakian A; Vallois P; Schvoerer E; Guillemin F
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence of anti-SARS-CoV-2 antibodies in residents of Karachi-challenges in acquiring herd immunity for COVID 19.
    Zaidi S; Rizwan F; Riaz Q; Siddiqui A; Khawaja S; Imam M; Naz A; Waheed S; Shamsi T
    J Public Health (Oxf); 2021 Apr; 43(1):3-8. PubMed ID: 32940328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
    Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
    Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.